ACCUSTEM SCIENCES INC | 10-Q: Quarterly report

SEC announcementMay 20 10:15 ET · Announcements

AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership

LONDON and PHOENIX, July 17, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, and EmeritusDX, a rapidly

GlobeNewswireJul 17, 2023 07:00 ET

AccuStem Sciences, Inc. Extends and Broadens Partnership With Instituto Europeo Di Oncologia (IEO) Enabling Its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer

StemPrintER outperformed the current market leader, OncotypeDX test, in stratifying patients according to their risk of breast cancer recurrence LONDON and PHOENIX, July 11, 2023 (GLOBE NEWSWIRE) -- AccuStem

GlobeNewswireJul 11, 2023 07:00 ET

Goldman Small Cap Research Publishes New Research Report on AccuStem Sciences, Inc.

BALTIMORE, MD / ACCESSWIRE / June 20, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new re

AccesswireJun 20, 2023 08:09 ET

AccuStem Sciences, Inc. Announces Collaboration Agreement With University Hospitals

AccuStem Sciences, Inc. (OTCQB: ACUT) today announced the establishment of a joint clinical collaboration agreement with University Hospitals.

GlobeNewswireJun 6, 2023 01:00 ET

AccuStem Announce Strategic Clinical and Operational Partnership

LONDON and PHOENIX, May 31, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today annou

GlobeNewswireMay 31, 2023 07:00 ET